Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site) - Incorporation of Mayo Clinic Cancer Center as an Affiliated Center

项目总结/摘要 提交本申请是为了请求为马约诊所癌症中心（MCCC）提供额外资金， Dana-Farber/哈佛癌症中心（DF/HCC）实验治疗学的附属组织（AO） 临床试验网络（ETCTN）领导学术组织（LAO）。由Alex A. Adjei和代表马约诊所罗切斯特、佛罗里达和亚利桑那的研究中心，已被纳入 DF/HCC LAO领导和指导委员会、治理委员会和翻译核心。 此外，在MCCC的支持下，他们作为以疾病为重点的临床研究者参与 介入放射学、病理学和生物统计学。在本补编下开展的工作将促进 继续并完成MCCC领导的ETCTN试验，解决DNA修复和肿瘤抑制剂 代谢，以及免疫肿瘤学组合和抗体药物缀合物跨越实体瘤， 血液恶性肿瘤。重点将放在继续指导MCCC早期职业生涯 研究人员，部分表现为DF/HCC LAO学者在癌症实验中提供的支持 治疗学（SCET）计划。作为一个AO，预计在未来一年，MCCC调查人员将 ETCTN试验至少入组20例患者，并提交项目团队成员申请（PTMA）， 其他临床试验提案，最终至少获得两份批准的意向书（LOI）。MCCC研究者 还将与国防部/总部合同委员会协调，确保LAO始终展示至少30%的网络 参与，在相关疾病重点学科中至少有6项试验开放，每种疾病入组10例 组最后，MCCC研究人员还将与DF/HCC合作，以增加以下患者的入组率- 通过利用MCCC涵盖的集水区， 网站.

PROJECT SUMMARY/ABSTRACT This application is being submitted to request additional funds for Mayo Clinic Cancer Center (MCCC) as an Affiliated Organization (AO) to the Dana-Farber/Harvard Cancer Center (DF/HCC) Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organization (LAO). MCCC investigators, led by Dr. Alex A. Adjei and representing the Mayo Clinic Rochester, Florida and Arizona sites, have been incorporated into the DF/HCC LAO Leadership and Steering Committee, Governance Committee and Translational Core. Additionally, they are participating as disease-focused clinical investigators, with support from MCCC interventional radiology, pathology and biostatistics. Work conducted under this supplement will facilitate the continuation and completion of MCCC-led ETCTN trials that address inhibitors of DNA repair and tumor metabolism, as well as immuno-oncology combinations and antibody drug conjugates across solid tumors and hematologic malignancies. Emphasis will be placed on the continued mentorship of MCCC early career investigators, manifested in part by support afforded by the DF/HCC LAO Scholars in Cancer Experimental Therapeutics (SCET) Program. As an AO, it is anticipated that over the next year, MCCC investigators will enroll a minimum of 20 patients to ETCTN trials and submit Project Team Member Applications (PTMAs) and other clinical trial proposals culminating in at least two approved letters of intent (LOIs). MCCC investigators will also coordinate with DF/HCC to ensure that the LAO consistently demonstrates at least 30% network participation, with at least 6 trials open in relevant disease-focused disciplines with 10 enrollments per disease group. Finally, MCCC investigators will also work with DF/HCC to increase the enrollment of under- represented and rural populations to ETCTN trials by leveraging the catchment area encompassed by MCCC sites.